Therefore, it is tempting to speculate the use of Breflate (a prodrug form of brefeldin-A, NSC656202) [53] to prevent cleavage of MUC16 and its associated tumorigenic functions as an interesting therapeutic avenue owing to the increased reliance of tumor cells on the secretory pathway than their normal counterparts [53,54]. Here, MUC16 is linked to neoplasm.